Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

VRX Investor Alert: Kyros Law is Investigating Legal Claims on Behalf of Valeant Pharmaceuticals Intl (NYSE: VRX) Investors

PR Newswire

BOSTON, Dec. 21, 2017 /PRNewswire/ -- Kyros Law Offices is alerting investors of Valeant Pharmaceuticals Intl (NYSE: VRX) that it is investigating legal claims against the company for possible securities fraud violations committed by Valeant Pharmaceuticals Intl (NYSE: VRX).

In the last few weeks, Kyros Law has been contacted by numerous investors that have lost hundreds of thousands of dollars invested in the company. Kyros Law is dedicated to fighting for the rights of these investors, and other investors that have lost money in VRX stock.

Valeant Pharmaceuticals Intl (NYSE: VRX) investors that have invested over $100,000 before March 2016 are urged to contact our law firm immediately to protect their rights. Visit our VRX Lawsuit website or call 1-800-934-2921 to speak to someone about your case.

The investigation concerns possible violations of securities law committed by Valeant Pharmaceuticals Intl (NYSE: VRX) management that has led to significant losses to investors. Recent lawsuits filed against the company allege that Valeant Pharmaceuticals Intl (NYSE: VRX) may have improperly used a pharmacy network to artificially increase sales for their drugs.

In February 2016, Valeant Pharmaceuticals Intl (NYSE: VRX) announced it would restate its financial results, citing issues with revenue recognition stemming from sales from a specific pharmacy network. That same month, the company came under SEC investigation. During this time, the stock price of VRX dropped significantly, with the share prices dropping more than 90%.

Kyros Law Offices urges Valeant Pharmaceuticals Intl (NYSE: VRX)  investors that invested more than $100,000 prior to March 2016 to contact our law firm immediately to protect their rights. Visit our VRX Lawsuit website or call 1-800-934-2921 to find out if you have a case.

Kyros Law specializes in a wide range of complex litigation, mass torts, and corporate governance matters, including the representation of whistleblowers, shareholders and consumers in securities fraud, false claims act and class actions. Our lawyers have been responsible for recovering hundreds of millions of dollars for our clients throughout the United States, Africa, Asia and Europe. Visit our website  to learn more about our firm.

Cision View original content:http://www.prnewswire.com/news-releases/vrx-investor-alert-kyros-law-is-investigating-legal-claims-on-behalf-of-valeant-pharmaceuticals-intl-nyse-vrx-investors-300574376.html

SOURCE Kyros Law



Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today